COVID-19 and liver dysfunction: Epidemiology, association and potential mechanisms - 27/02/22
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Highlights |
• | About 2.0%–4.9% of coronavirus disease 2019 (COVID-19) patients had preexisting liver diseases. The relationship between preexisting liver diseases and adverse outcomes is inconsistent and needs to be explored in a cohort study. |
• | Liver involvement in COVID-19 may affect about 16%–29% of patients. The manifestations of liver injury mainly include elevated aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels. |
• | Most evidence has indicted that liver injury and specific liver biochemical markers are associated with COVID-19 mortality and severity. |
• | The mechanisms are complex and include direct cholangiocyte damage induced by severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), cytokine storm, and drug-induced liver injury. Drug-induced liver injury may be the most important reason. |
Abstract |
Currently, there have been more than one hundred million confirmed cases of coronavirus disease 2019 (COVID-19), with two million deaths worldwide. This has caused a huge medical burden. Severe COVID-19 patients can experience multi-organ damage, including cardiac injury, kidney injury, and liver injury. About 2.0%–4.9% of COVID-19 cases involve patients with preexisting liver diseases. Additionally, preexisting liver diseases were reported and associated with severity (odds ratio (OR) or risk ratio (RR) = 1.48–1.70) and mortality (OR or RR = 1.08–2.65) among COVID-19 patients. Furthermore, the prevalence of liver injury was 16%–29% in COVID-19 patients. Higher prevalence of liver injury may worsen prognosis in patients (severity: OR or RR = 1.9–2.6; mortality: OR or RR = 1.1–4.0). The mechanisms of this association between liver injury and severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection are complex, including direct cholangiocyte damage induced by SARS-COV-2, cytokine storm, and drug-induced liver injury. In particular, drug-induced liver injury may be the most important reason. This review discusses the epidemiology of COVID-19 and liver dysfunction as well as potential mechanisms underlying the association between COVID-19 and liver dysfunction or other preexisting liver diseases. However, the association between preexisting liver diseases and COVID-19 prognosis and potential mechanisms underlying these associations require further prospective studies.
Le texte complet de cet article est disponible en PDF.Keywords : Liver dysfunction, COVID-19, Systematic review
Plan
| COVID-19 and Liver Dysfunction: Epidemiology, Association, and Potential Mechanisms |
Vol 46 - N° 2
Article 101793- février 2022 Retour au numéro
Article précédent
- Advances in cell death - related signaling pathways in acute-on-chronic liver failure
- Liqiao Huang, Jie Liu, Caiqun Bie, Helu Liu, Yichun Ji, Dongfeng Chen, Meiling Zhu, Weihong Kuang
- Homeostatic regulation of food intake
- Lizeth Cifuentes, Andres Acosta
Bienvenue sur EM-consulte, la référence des professionnels de santé.